Anti-angiogenic Therapy Versus Dose-Dense Paclitaxel Therapy for Frontline Treatment of Epithelial Ovarian Cancer: Review of Phase III Randomized Clinical Trials
- 359 Downloads
The investigation of anti-angiogenic agents and dose-dense paclitaxel therapy in epithelial ovarian cancer is an active area of research. To date several phase III trials have shown both approaches to be effective strategies for the frontline treatment of ovarian cancer over standard every 21 day chemotherapy alone. However, most of the improvement is seen only in progression-free survival, with added toxicity (e.g., hypertension, diarrhea, sensory neuropathy, fatigue). Subset analyses based on clinical predictors (e.g., residual disease) have been able to identify patients more likely to benefit from anti-angiogenic agents. And more recently, molecular profiling of tumor genetics has shown similar promising results. Ongoing research will help enhance our ability to match patients to therapeutic strategies most likely to optimize outcomes and minimize risk.
KeywordsOvarian cancer Anti-angiogenesis Oncology Dose dense Toxicity Gynecological cancer
Compliance with Ethics Guidelines
Conflict of Interest
Katrina N. Slaughter declares no conflict of interest.
Kathleen N. Moore reports personal fees from Genentech, Immunogen, Advaxis, and Boehringer Ingelheim, outside the submitted work.
Robert S. Mannel has received grants and/or personal fees from Genentech, Amgen, AstraZeneca, Genentech, Endocyte, Eisai, Advaxis, Medimmune, and Oxigene.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
- 2.Brown MR, Blanchette JO, Kohn EC. Angiogenesis in ovarian cancer. Bailliere’s best practice and research. Clin Obstet Gynaecol. 2000;14:901–18.Google Scholar
- 8.Randall LM, Burger RA, Nguyen H, Kong G, Bookman MA, Fleming GF, et al. Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab. Gynecol Oncol. 2013;130 (1);e33–e34.Google Scholar
- 10.Du Bois A, Floquet A, Weon Kim J, Rau J, Del Campo JM, Friedlander M, et al. Randomized double blind phase III trial of pazopanib versus placebo in women who have not progressed after first line chemotherapy for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16). J Clin Oncol. 2013;31(No 18 suppl; Abstr LBA 5503)Google Scholar
- 11.GlaxoSmithKline (GSK) Regulatory update: Votrient (pazopanib) as maintenance therapy for advancaed ovarian cancer in the EU. http://www.gsk.com/en-gb/media/press-releases/2014/regulatory-update-votrient-pazopanib-as-maintenance-therapy-for-advaned-ovarian-cancer-in-the-eu/ Accessed 31 Mar 2014
- 12.Du Bois A, Kristensen G, Ray-Coquard I, Reub A, Pignata S, Colombo N, et al. AGO-OVAR 12: A randomized placebo-controlled GCIG/ENGOT Intergroup phase III trial of standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer. Int J of Gynecol Cancer. 2013;23(8 Suppl 1):7–8Google Scholar
- 13.Ledermann JA, Perren TJ, Raja FA, Embleton A, Rustin GJS, Jayson G, et al. Randomized double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. European J of Cancer 2013;49(Suppl 3):Abract 10Google Scholar
- 14.A prospective, phase III, randomized, double blind placebo controlled trial evaluating adding trebananib to carboplatin and paclitaxel in the upfront treatment of patients with advanced stage ovarian cancer (NCT01493505). http://clinicaltrials.gov. Accessed 6 Jun 2014.
- 15.Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, et al. A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1. European J of Cancer 2013;49(suppl 3):Abstract 41Google Scholar
- 17.Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase III randomized trial. Lancet Oncol. 2013;14:236–43.PubMedCrossRefPubMedCentralGoogle Scholar
- 22.du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundgvist E, et al. consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIGOCCC 2004). Ann Oncol. 2005;16 Suppl 8:viii7–12.PubMedGoogle Scholar
- 23.Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with tratuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008;26:1642–9.PubMedCrossRefGoogle Scholar
- 25.Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomized, controlled, open-label trial. Lancet. 2013;14:1020–6.PubMedCrossRefGoogle Scholar
- 26.Chan J, Brady M, Penson RT, Monk B, Boente M, Walker J, et al. Phase III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT01167712). Int J of Gynecol Cancer 2013;23(8 suppl 1):9-10Google Scholar
- 28.An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT01654146). http://clinicaltrials.gov. Accessed 18 Jul 2014.
- 30.Gourley C, McCavigan A, Perren T, Paul J, Michie CO, Churchman M, et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. J Clin Onc 32:5s,2014;(suppl; abstr 5502)Google Scholar
- 31.Winterhoff BJN, Kommoss S, Oberg AL, Wang C, Riska SM, Konecny GE, et al. Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer. J Clin Oncol 32:5s, 2014;(suppl; abstr 5509)Google Scholar